Triple-negative breast cancer (TNBC) is highly aggressive, difficult to treat and commonly develops visceral metastasis, including lung metastasis. We observed that High mobility group box 1 protein (HMGB1) was highly expressed in human TNBC and positively correlated with cancer metastasis. The hypoxic tumor environment is known to regulate HMGB1 secretion, but an understanding of the underlying mechanism by which tumor-derived HMGB1 regulates interstitial components and promotes breast cancer lung metastasis has remained elusive. The results of the present study showed that the number of CD62L neutrophils, which have a strong ability to produce neutrophil extracellular traps (NETs), increased significantly in both peripheral blood and lung tissues in a mouse TNBC model and were regulated by tumor-derived HMGB1 through the TLR2 pathway. Furthermore, serum HMGB1 levels were positively correlated with CD62L neutrophils in 86 breast cancer patients. We demonstrated that CD62L neutrophils accelerated lung metastasis and that interventions targeting the "HMGB1-CD62L neutrophil-NETs" axis could inhibit lung metastasis. Our results suggest that the combination of HMGB1 and CD62L neutrophils is a potential marker for breast cancer lung metastasis and is novel target for future prevention and therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499196 | PMC |
http://dx.doi.org/10.1038/s41389-020-00267-x | DOI Listing |
Biomed Eng Online
January 2025
Department of Medical Ultrasound, Maoming People's Hospital, Maoming, Guangdong, 525011, People's Republic of China.
Background: Epidermal growth factor receptor (EGFR) gene mutations can lead to distant metastasis in non-small cell lung cancer (NSCLC). When the primary NSCLC lesions are removed or cannot be sampled, the EGFR status of the metastatic lesions are the potential alternative method to reflect EGFR mutations in the primary NSCLC lesions. This review aimed to evaluate the potential of magnetic resonance imaging (MRI) radiomics based on extrapulmonary metastases in predicting EGFR mutations through a systematic reviews and meta-analysis.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
January 2025
Medical Research Center, Binzhou Medical University Hospital, Binzhou, Shandong, 256600, P.R. China.
Purpose: Immune checkpoint blockades (ICBs) are promising, however they do not fit all types of tumor, such as those lack of tumor antigens. Induction of potent anti-tumor T cell immunity is critical for cancer therapy. In this study, we investigated the efficacy of immunotherapy via the immunogenic cell death (ICD) dying tumor cells in mouse models of lung metastasis and tumorigenesis.
View Article and Find Full Text PDFJACC Case Rep
January 2025
Department of Cardiovascular Magnetic Resonance, Hôpital Privé Jacques Cartier, Institut Cardiovasculaire Paris Sud, Massy, France.
Although relatively rare, cardiac metastases represent a significant clinical challenge because of their impact on cardiac function and overall patient prognosis. This case presents a rare and atypical presentation of a patient with ventricular arrhythmia revealing a metastatic cancer in the heart. A 59-year-old man with lung cancer was admitted for chest tightness and episodes of syncope.
View Article and Find Full Text PDFEndocr Oncol
January 2024
Centro de Investigación Biomédica en Red, CIBERONC, ISCIII, Madrid, Spain.
While the role of cancer stem cells (CSCs) in tumorigenesis, chemoresistance, metastasis, and relapse has been extensively studied in solid tumors, such as adenocarcinomas or sarcomas, the same cannot be said for neuroendocrine neoplasms (NENs). While lagging, CSCs have been described in numerous NENs, including gastrointestinal and pancreatic NENs (PanNENs), and they have been found to play critical roles in tumor initiation, progression, and treatment resistance. However, it seems that there is still skepticism regarding the role of CSCs in NENs, even in light of studies that support the CSC model in these tumors and the therapeutic benefits of targeting them.
View Article and Find Full Text PDFAm J Transl Res
December 2024
Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Tianjin 300070, China.
Proteinase-activated receptor-2 (PAR2) is closely linked to tumor malignancy, but its biological role in cancer remains underexplored. In this study, we assessed PAR2 expression in lung adenocarcinoma (LUAD) and normal lung tissues, analyzed associations between clinicopathological features and survival rates, and confirmed that PAR2 promotes apoptosis resistance and reduces cisplatin-induced cytotoxicity in lung cancer cells. Using TCGA datasets, western blotting, qPCR, and immunohistochemistry (IHC), we observed a significant increase in PAR2 levels in LUAD samples compared to normal tissues (P<0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!